生物制药公司Upstream Bio近日宣布，其用于治疗重症哮喘的在研药物Verekitug，在II期Valiant临床试验中取得了积极的顶线结果。
该试验数据表明，Verekitug在主要疗效终点上表现出显著优势，达到了预设的统计学标准。这一积极结果标志着Verekitug在治疗重症哮喘这一未满足巨大医疗需求的领域取得了重要进展，为后续的临床开发奠定了坚实基础。
生物制药公司Upstream Bio近日宣布，其用于治疗重症哮喘的在研药物Verekitug，在II期Valiant临床试验中取得了积极的顶线结果。
该试验数据表明，Verekitug在主要疗效终点上表现出显著优势，达到了预设的统计学标准。这一积极结果标志着Verekitug在治疗重症哮喘这一未满足巨大医疗需求的领域取得了重要进展，为后续的临床开发奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.